Company intelligence / Profile preview

Biotie Therapies

Turku, Western FI, Finlandorpha.net ↗

Ownership: Private
Employees: ~38
Development stage: Other

Overview

Biotie's most advanced product was Selincro® for alcohol dependence—approved and marketed in Europe by Lundbeck. Tozadenant reached Phase 3 trials for Parkinson’s disease as an adjunct to levodopa. SYN120 completed early clinical studies targeting cognitive/psychotic symptoms. BTT1023 was a Phase 2 mAb program for primary sclerosing cholangitis with orphan drug designation. The company had additional preclinical assets but focused on CNS and liver indications at the time of its acquisition by Acorda Therapeutics in January 2016

Therapeutic areas: PulmonologyPsychiatryGastroenterologyNeurology
Modalities: Small moleculesmonoclonal antibodies (mAbs)biologics
Industry: Biotech

Drug pipeline

3 assets

timolumab

2 more assets in the full pipeline.

Request access →

Partnerships

H.Lundbeck A/S(Selincro commercialization)UCBRoche(legacy asset licenses via Synosia deal)Seikagaku(VAP‑1 antibody rights Asia-Pacific)

Beyond the preview

Go deeper on Biotie Therapies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biotie Therapies.

Explore the full profile